Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)

Trial Profile

Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Feb 2011

At a glance

  • Drugs Bremelanotide (Primary)
  • Indications Female sexual dysfunction; Menopause
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Palatin Technologies
  • Most Recent Events

    • 27 Sep 2007 Primary endpoint met; top-line results reported in a Palatin media release.
    • 27 Sep 2007 Status changed from in progress to completed.
    • 27 Feb 2007 Interim results have been reported.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top